文献速递神经核医学

FDG PET脑显像用于筛查老年肝移植候选者的神经退行性疾病

FDG PET of the brain to screen for neurodegenerative disease in older liver transplant candidates.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-06-05

本初步研究纳入18例肝移植评估期间临床怀疑痴呆的患者,行脑FDG PET/CT并与神经心理测试(NPT)比较。FDG PET/CT诊断不可逆性痴呆病因者占40%,与NPT一致性中等(K=0.44),敏感度100%、特异度50%,诊断时间12.4天较NPT的73.1天显著缩短。作者认为FDG PET/CT有助于筛查,但阳性结果需进一步评估后方可拒绝可能挽救生命的治疗。

要点

  • 18例肝移植候选者中40%经FDG PET/CT诊断不可逆性痴呆病因。
  • FDG PET/CT与NPT一致性中等(K=0.44),敏感度100%、特异度50%。
  • FDG PET/CT诊断时间12.4天,较NPT的73.1天显著缩短。

核心结论

  • 作者认为FDG PET/CT有助于筛查老年肝移植候选者的不可逆性痴呆病因,但阳性PET提示在拒绝患者可能挽救生命的治疗前需进一步评估。
  • 作者认为FDG PET/CT可作为老年肝移植评估患者痴呆的敏感初筛试验,并可通过NPT或更特异的神经退行性疾病生物标志物确认。

研究设计与样本

  • 初步研究,纳入18例肝移植评估期间临床怀疑痴呆的患者行脑FDG PET/CT。
  • 收集人口学数据、FDG PET/CT与NPT结果及从开具医嘱到判读的时间,计算二者一致性与诊断时间。
  • 将患者FDG PET/CT与健康年龄匹配对照比较,确定脑内FDG摄取改变模式。

主要发现

  • 40%的患者经FDG PET/CT诊断不可逆性痴呆病因。
  • NPT与FDG PET/CT之间一致性中等(K=0.44)。
  • FDG PET/CT敏感度100%、特异度50%。
  • FDG PET/CT诊断时间12.4天,较NPT的73.1天显著缩短。
  • 体素分析显示肝移植评估患者较年龄匹配健康对照存在弥漫性皮质和基底节代谢减低,差异有统计学意义。

临床怎么用

  • 作者认为FDG PET/CT可作为老年肝移植评估患者痴呆的敏感初筛试验,阳性结果需进一步评估后方可拒绝可能挽救生命的治疗。
  • 作者认为FDG PET/CT筛查结果可通过NPT或更特异的神经退行性疾病生物标志物确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aging liver transplant population presents new challenges in distinguishing irreversible, age-related causes of dementia from hepatic encephalopathy (HE), given their overlapping clinical presentations. Dementia is often assessed through neuropsychological testing (NPT), but imaging utilizing biomarkers like Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) has been considered as an alternative. This preliminary investigation aims to assess FDG PET/CT in screening for irreversible causes of dementia in older liver transplant candidates. METHODS: Eighteen patients with clinical suspicion for dementia during transplant evaluation were assessed using FDG PET/CT of the brain. Demographic data, FDG PET/CT and NPT results, and time between date of order and interpretation of FDG PET/CT and NPT were collected. Concordance between and time-to-diagnosis of FDG PET/CT and NPT were calculated. FDG PET/CT of these patients were compared to healthy, age-matched controls to determine altered patterns of FDG uptake in the brains of these patients. RESULTS: 40% of patients were diagnosed with an irreversible cause of dementia on FDG PET/CT. There was moderate agreement (K = 0.44) between NPT and FDG PET/CT. FDG PET/CT had a sensitivity and specificity of 100% and 50%, respectively. Time-to-diagnosis was significantly shorter with FDG PET/CT (12.4 days) compared to NPT (73.1 days). Voxel-wise analysis showed statistically significant diffuse cortical and basal ganglia hypometabolism in patients being evaluated for liver transplant versus age-matched healthy controls. CONCLUSION: FDG PET/CT is helpful in screening for irreversible causes of dementia in older liver transplant candidates, but a positive PET indicates that further evaluation is required before denying a patient a potentially life-saving treatment. Efficient workup for these patients is crucial, and FDG PET/CT could provide a sensitive first screening test for dementia in older patients undergoing liver transplant evaluation which can be confirmed with NPT or with more specific biomarkers of neurodegenerative disease. CLINICAL TRIAL REGISTRATION: Not applicable.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jones N, Schwartz TM, Bishay S, et al. FDG PET of the brain to screen for neurodegenerative disease in older liver transplant candidates. Eur J Nucl Med Mol Imaging. 2025. PMID: 40471321. doi:10.1007/s00259-025-07382-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。